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ABSTRACT A cutaneous adverse drug reaction (CADR) is any undesirable change in 
the structure or function of the skin, its appendages, or mucous membranes caused 
by a drug. The frequency of CADRs is variable, with only few studies evaluating it. 
Our aim was to identify the clinical spectrum of CADRs and document the epidemio-
logical data of different types of drug eruptions among Egyptian patients attending 
a tertiary care center. An observational hospital-based analytical study was planned 
for a period of six months (January-June 2015). All patients attending the outpatient 
Dermatology Clinic at Kasr El Aini hospital were examined to detect patients with 
CADRs, who were subjected to a detailed questionnaire with a detailed drug history. 
A skin biopsy was taken to confirm the diagnosis and to detect the type of CADRs. 
The primary incidence of CADRs reported in our study was 0.28% (78 patients) from 
a total number of 27,093 patients. The most common CADRs were SJS/TEN in 12 pa-
tients (15.3%) and lichenoid drug eruptions in 12 patients (15.3%), followed by ex-
anthematous drug eruptions in 11 patients (14.1%) and vasculitic drug eruptions in 
9 patients (11.5%). The most common drug incriminated was ibuprofen in 6 patients 
(7.6%), followed by penicillin in 4 patients (5.1%) and aspirin in 3 patients (3.8%). 
In conclusion, incidence of CADRs in our study was similar to incidence reported 
in different countries; however, the incidence of life-threatening reactions such as 
SJS/TEN was higher compared with studies conducted abroad. 
KEY WORDS: cutaneous adverse drug reactions, epidemiology, incidence, outpa-
tients
INTRODUCTION
Constant advancements in the medical and phar-
macological fields and development of new drugs 
contribute to the increasing number of cutaneous 
drug reactions reported every year. But the true in-
cidence of drug eruptions is difficult to determine, 
mainly because many mild and transitory reactions 
are not recorded (1).
A cutaneous adverse drug reaction (CADR) is any 
undesirable change in the structure or function of the 
skin, its appendages, or mucous membranes caused 
Abbreviations:
AGEP: Acute generalized exanthematous pustulosis 
CADRs: Cutaneous adverse drug reactions
DIHS: Drug-induced hypersensitivity syndrome 
DRESS: Drug rash with eosinophilia and systemic symp-
toms
FDEs: Fixed drug eruptions 
GBFDE: Generalized bullous fixed drug eruption
NSAIDs: Nonsteroidal anti-inflammatory drugs
SCARs: Severe cutaneous adverse reactions 
SD: Standard deviation
SJS: Steven-Johnson syndrome
TEN: Toxic epidermal necrolysis
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by a drug (2). Almost any medication can induce skin 
reaction, and certain drug classes such as nonsteroi-
dal anti-inflammatory drugs (NSAIDs), antibiotics, and 
antiepileptics have drug eruption rates approaching 
1-5% (3).
CADRs are the most frequent of all manifestations 
of drug sensitivity and manifest with varied and di-
verse morphology (2). The majority of eruptions are 
mild and self-limiting (3), ranging from skin rashes, 
urticaria, fixed drug eruption, angioedema, and ery-
thema multiforme (4). Severe cutaneous adverse re-
actions (SCARs) include Stevens Johnson syndrome 
(SJS), toxic epidermal necrolysis (TEN), drug-induced 
hypersensitivity syndrome (DIHS), and drug rash with 
eosinophilia and systemic symptoms (DRESS). Acute 
generalized exanthematous pustulosis (AGEP) has 
been added to the list comprising SCARs (5). 
The prevalence, clinical patterns, and causative 
drugs of CADRs vary among the different populations 
previously studied, comprising 10-30% of all reported 
adverse drug reactions (6). Since drug reactions are a 
major cause of patient morbidity and account for a 
significant number of patient deaths (7), it is there-
fore of utmost necessity for a dermatologist to pos-
sess a comprehensive understanding of the clinical 
spectra of CADRs as well as knowledge of the drugs 
which are frequently incriminated in such adverse re-
actions. This would help reduce or minimize the ex-
tent of iatrogenic morbidity and mortality (2) and is 
why special attention to monitoring and reporting of 
CADRs must be encouraged. Since the bulk of CADRs 
result from physician-prescribed drugs, awareness on 
part of the physician can help in their timely detec-
tion and management, thereby restricting the associ-
ated damage (8).
PATIENTS AND METHODS
The study was designed as an observational hos-
pital-based analytical study. It was conducted at the 
outpatient clinic of the Dermatology Department, 
Faculty of Medicine, Cairo University Hospital (Kasr El 
Aini) over a period of six months (January-June 2015). 
After approval by the Dermatology Research Ethical 
Committee, written informed consent was obtained 
from each patient for the participation in the study 
and photography.
Patients
All patients with a clinical picture of CADRs at-
tending the Dermatology Outpatient Clinic fulfilling 
the inclusion and exclusion criteria were included. 
The inclusion criteria included adults over 18 years of 
age with visible skin eruptions and with a history of 
drug intake. The exclusion criteria excluded patients 
whose skin lesions turned out to be disease-related 
(e.g. viral exanthems). Each patient was subjected to 
proper history taking, detailed drug history, and gen-
eral and skin examinations. 
METHODS
Clinical evaluation
After initial assessment by the investigator based 
on patient history and a general and cutaneous ex-
amination according to a predefined questionnaire 
for CADRs (Table 1) including detailed drug history, 
observers A and B both independently evaluated the 
cases clinically or by clinical photographs, and a pro-
visional clinical diagnosis or a clinical differential diag-
nosis was suggested by the investigators. CADRs were 
classified according to their characteristic skin features 
into severe and non-severe types (9) (Table 2).
Skin biopsy and histopathological evalu-
ation
If the patient had multiple similar lesions, only one 
representative biopsy was taken using a 4 mm punch 
biopsy. Biopsy was fixed in 10% neutral buffered for-
malin followed by embedding in paraffin. Routinely 
stained hematoxylin and eosin (H&E) slides were pre-
pared. Light microscopic examination was carried out 
for the slides.  
Histopathological diagnosis was based on the 
histopathological clues described in literature. A final 
diagnosis was established for each case based on the 
clinico-pathological correlation (10-12) (Table 3). 
The data was coded, revised, and checked using 
the statistical package SPSS version 16.0. Data trans-
formation, recoding, and grouping was performed 
regarding both severity and types of drug reaction. 
The severity classification into severe types of drug 
eruption and other types of drug eruptions was ad-
hered to (9). Differences between the studied groups 
were assessed using the suitable inferential statistical 
tests. The student’s t-test and one-way ANOVA test 
were used for quantitative independent variables re-
garding two or more levels and for dependent vari-
ables, respectively. The differences between qualita-
tive variables were assessed using the chi-square test. 
All the above mentioned statistical tests were consid-
ered significant at a P-value <0.05.
RESULTS
A total of 78 patients with CADRs was reported, 
while the total number of patients attending the der-
matology clinic during the study period was 27,093 
El-Nabarawy et al. Acta Dermatovenerol Croat
Epidemiological analysis of drug reactions  2018;26(3):233-242
ACTA DERMATOVENEROLOGICA CROATICA 235
Table 1. Cutaneous adverse drug reaction patient questionnaire:
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Personal history Date:
Name:                                                                                    
Residence:         Governorate:
Area : ○ Rural  ○ Urban/slum ○ Urban/non slum
Age: ( in years)  :                                                                                    
Occupation: ○ House wife   ○ Non working   ○ Manual worker   ○ Farmer   
○ Trades/Business   ○ Clerk   ○ Semi-professional  ○ Professional    ○ Others
Gender:    ○ male     ○ female                                                                                   Tel. no :
Marital status:    ○ married    ○single   ○ divorced   ○ widow                                                           
Special habbits:   ○ NO special habbits  ○Smoking  ○Alcohol   ○Drugs
Education:   ○Illiterate    ○ Read & write     ○ Primary     ○ Preparatory         
○ Secondary (general or technical)   ○Intermediate (2 years)     ○ University graduate   ○ Postgraduate  degree 
Drug exposure 
history 
Name of the drug:    ● Category (antibiotics, antiepileptics…):       
  ●Do not remember the drug 
Nature of medication:   ○ Capsules    ○Tablets     ○Powder      ○Eye drops    ○Liquid    ○Inhalants     ●Skin preparations   
○Ointment   ○Cream   ○Lotion          ●Suppositories ○Vaginal ○Rectal
Dose:
Cumulative dose:
Route of administration:     ○Oral      ○Topical     ○Parenteral      ○Rectal     ○Inhaled  ○Intradermal
Duration of drug intake (in days):
Duration between initiation of the drug and the onset of the eruption (in days):
Duration of the eruption ( in days ):
Course of the eruption:   ○Progressive        ○Regressive        ○Stationary
Course of the eruption after withdrawal of the offending drug: ○ Progressive    ○ Regressive   ○ Stationary
Improvement after decrease dosage or discontinuation of the drug (dechallenge): ○Yes       ○No
The re-exposure to a drug and the exacerbation of eruption (rechallenge):      ○Yes       ○ No
Responsible drug (suspected drug probability):   ○ High        ○ Medium     ○ Low
Previous attacks:    ○Yes      ○  No 
Past history and 
general medical 
history 
○ Viral disease   ○ Autoimmune disease    ○ CTD    ○ Malignancy  
○ Others ○ None                           
Family history Other diseases: ○ CTD    ○ Autoimmune      ○ Drug reactions      . clinical presentation:       ○ None




Sunlight, artificial tanning devices: ○Yes         ○No
Clinical picture a.Vital signs:   ○ Fever    ○ Hypotension   ○ Others
b.Systemic symptoms:   ○ Pruritis    ○ Facial edema     ○ HSM   ○ Others
c. LNS:      ○Generalized          ○Localized     ○ None
d.Lesions:    
   Primary lesion: ○Macules ○Papules ○Patches ○Nodules ○Wheal   ○Plaques ○Vesicles ○Tumor ○ Bullae  ○ Comedones           
○Pustules ○Palpable purpura   ○Targetoid lesions    ○ Edema of SC tissue  
   Secondary lesions:  ○ Scales ○Crusts○ Excoriations ○Abrasions ○Fissures ○ Ulcers  ○Necrosis    ○Erosion   ○Others            
    Pigmentations:      ○ Yes       ○ No
e. Distribution:  ○ Generalized   ○ Acral    ○ Photodistribution     ○Grouping   ○ Localized
f. Site:    ○ Scalp   ○ Face       ○ Arm  ▫  B▫   F         ○ Forearm   ▫B   ▫F        ○ Hand   ▫D    ▫P           ○T runk   ▫ B   ▫F        ○ Thigh   ▫B    
▫F        ○ Leg    ▫ B    ▫F         ○ Foot  ▫ D     ▫P
(B:back,F:front, D:dorsal, P:palmo  plantar)
g. Mucous membrane:   ○ Ocular   ○Nasal     ○ Genital      ● Oral ○ Labial ○ Buccal  ●None
h.Type of eruption:  ○ Macular   ○ Papular  ○ Exanthematous DE  ○ Pustular (AGEP)    ○ Vesicular    ○ Bullous    ○ Fixed    
○Generalized fixed DE ○ Urticarial ○ Vaculitic  ○Lichenoid  ○Acneiform   ○ Psoriasiform  ○Lymphomatoid  ○ Erythrodermic   
○ Angioedema ○ Others  
i. Clinical diagnosis:                                     
Biopsy     ●Site:                         ●  No.:                                   ● Date:        ○ 24hrs    ○48hrs     ○72hrs     ○Others                 ○Refused                  
 ● Result:
CADRs: cutaneous adverse drug reactions, TEN: toxic epidermal necrolysis
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patients. The primary incidence of reported CADRs in 
our study was 0.28%. They included 78 patients, 29 
men (37.1%) and 49 women (62.8%) with a male to fe-
male ratio of 1:1.69. Ages ranged from 18-80 years of 
age with a mean of 41.7±14.84 years (mean ± SD). A 
comparison of the demographic parameters in both 
severe CADRs and other non-severe types of CADRs 
regarding sex, age, education, occupation, and total 
number of patients showed no statistically significant 
difference (P-value >0.05). 
Types of CADRs
The most common CADRs in our study were SJS/
TEN (15.3%) and lichenoid drug eruptions (15.3%), 
followed by exanthematous drug eruptions (14.1%) 
and vasculitic drug eruptions (11.5%) as shown in Fig-
ure 1. 
The most common drug category in each type of 
CADRs (Table 5)
There were 40 patients (51.0%) who could not re-
call the name of the drug, while 38 patients (48.7%) 
could recall the name of the drug. The most common 
drug incriminated in patients with CADRs was ibupro-
fen (7.7%), followed by penicillin (5.1%) and aspirin 
(3.9%). Antibiotics were the most common drug cat-
egory causing SJS/TEN, exanthematous drug erup-
tions, and urticarial drug eruption. Analgesics were 
the most common incriminated drug category caus-
ing fixed drug reactions (FDEs), lichenoid drug erup-
tions, and vasculitic drug eruptions. Anticonvulsants 
were the most common incriminated drug category 
causing psoriasiform drug eruption.
Duration of drug intake, duration between initia-
tion of the drug and onset of the reaction, and the 
duration of the eruption (Table 6)
A comparison of the duration of drug intake, du-
ration between initiation of the drug and onset of 
the reaction, and the duration of the eruption in se-
vere CADRs versus other non-severe types of CADRs 
showed a statistically significant longer duration in 
other non-severe types of CADRs (P-value = 0.008, 
0.040, and 0.010 respectively).
Other related parameters
A comparison of the route of administration and 
the nature of medication taken in severe versus other 
non-severe types of drug reactions showed no sta-
tistically significant difference. A comparison of the 
disease course regarding previous attacks, respon-
sible drug probability, re-challenge, de-challenge, 
course of the eruption, and course of the eruption af-
ter withdrawal of the offending drug in severe types 
of CADRs versus other non-severe types of CADRs, 
showed no statistically significant difference. A com-
parison of the associated risks regarding family histo-
ry of hypersensitivity syndrome, past medical history, 
and associated diseases in severe CADRs versus other 
non-severe types of CADRs showed no statistically 
significant difference.
Table 2. Classification of cutaneous adverse drug reactions (CADRs) into severe and non-severe types
Severe CADRs 1. Steven-Johnson syndrome and Toxic epidermal necrolysis     
2. Generalized bullous fixed drug eruption
3. Acute generalized exanthematous pustulosis
4. Drug reaction with eosinophilia and systemic symptoms 
5. Anaphylaxis
Non-severe CADRs 1. Exanthematous or maculo-papular drug eruption
2. Fixed drug eruption
3. Angioedema and urticarial drug eruption
4. Erythema multiforme
5. Psoriasiform drug eruption
6. Lichenoid drug eruption
7. Vasculitic drug eruption
8. Acneiform drug eruption
9. Hyperpigmentation and ochronosis
10. Cutaneous lymphoid hyperplasia
11. Erythrodermic drug reaction
Figure 1. Different types of cutaneous adverse drug 
reactions (CADRs) in our study.  
*TEN: toxic epidermal necrolysis 
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Type of drug 
eruption





-Timing after drug intake: 7–21 days 
-Type of skin lesions: Dusky and/or dusky-red 
macules with epidermal detachment and 
erosions, macular atypical targets, bullous 
lesions, 10->30% BSA detachment 
-Distribution: trunk, face, neck, elsewhere
-Mucosal involvement: severe 
-Systemic manifestations: fever, 
lymphadenopathy, hepatitis, cytopenias, 
nephritis
Variable epidermal apoptosis associated 
with basal cell hydropic degeneration or 
subpidermal vesiculation. A little superficial 
perivascular infiltrate predominantly 
lymphocytic with melanophages and few 
eosinophils. 
Generalized bullous 
fixed drug eruption 
-Timing after drug intake: 1st exposure: 1-2 
weeks, re-exposure: <48 hours
-Type of skin lesions: generalized 
erythematous edematous plaques are seen, 
sometimes they have a dusky violaceous 
hue developing vesiculobullae and become 
erosive, and upon readministration of the 
causative drug, lesions recur in exactly the 
same sites.
-Distribution: anywhere
-Mucosal involvement: numerous 
mucocutaneous lesions
In acute lesions: 
Marked basal hydropic degeneration 
with lymphocyte tagging along the 
dermoepidermal junction and individual 
keratinocyte necrosis. Marked pigmentary 
incontinence is a typical feature. 
Subepidermal vesiculation in advanced cases. 
Lymphocytes, histiocytes and neutrophils are 





-Timing: < 4 days
-Type of skin lesions: numerous small, non-
follicular sterile pustules; can coalesce leading 
to large areas of exfoliation
-Distribution: beginning on the face or in the 
major intertriginous zones (i.e. axillae and 
groin), followed by dissemination over a few 
hours.
-Systemic manifestations: high fever, 
peripheral neutrophilia
-Mucosal involvement: in 50% of patients
Subcorneal and or intraepidermal pustule 
full of neutrophils and few acantholytic cells. 
Spongiosis, edematous dermal papillae 
and may be subepidermal vesiculation. 
A perivascular infiltrate of lymphocytes, 
histiocytes, many neutrophils and may be 
eosinophils. Leukocytoclastic vasculitis in 
advanced lesions.




-Type of skin lesions: widespread erythema, 
vesiculobullae and pustules, facial edema 
(hallmark of DRESS), maculopapular 
rash developing >3 weeks after starting 
therapy, prolonged clinical symptoms after 
discontinuation of the causative drug
-Distribution: generalized
-Systemic manifestations: peripheral 
eosinophilia (>1.5 × 109/L), fever (>38 °C), 
liver abnormalities, leukocyte abnormalities 
(leukocytosis, atypical eosinophilia), 
lymphadenopathy and HHV-6 reactivation, 
nephritis, myocarditis, interstitial pneumonitis, 
myositis, thyroiditis
-Mucosal involvement: mild if present
Pathological features are non-specific 
according to the type of skin lesions.
Anaphylaxis -Timing: within minutes
-Type of skin lesions: combines skin signs of 
urticaria and/or angioedema, may be absent
-Distribution: generalized
-Systemic manifestations: hypotension and 
tachycardia, even cardiovascular shock
-Mucosal involvement: severe edema
Urticaria: Variable dermal edema and 
sparse perivascular and interstitial mixed 
inflammatory infiltrate composed of 
lymphocytes, neutrophils, and eosinophils.
Severe 
CADRs
Table 3. Clinical and histopathological criteria of cutaneous adverse drug reaction (CADRs) (10-12)
Non- severe 
CADRs
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-Type of skin lesions: symmetrically distributed 
pruritic erythematous macules, papules, and/
or urticarial lesions 
-Distribution: initially on the trunk and upper 
extremities; over time they can become 
confluent
-Systemic manifestations: low grade fever
-Mucosal involvement: spared
Normal epidermis or commonly focal 
parakeratosis is seen. The characteristic 
changes include mild spongiosis with 
lymphocyte exocytosis associated with 
basal cell liquefactive degeneration and 
few dyskeratotic cells. Perivascular infiltrate 
of lymphocytes, histiocytes and variable 
eosinophils.
Fixed drug eruption -Timing after drug intake: first exposure: 1-2 
weeks, re-exposure: <48 hours
-Type of skin lesions: one or a few, round 
to oval, sharply demarcated, erythematous 
edematous plaques are seen, sometimes 
they have a dusky violaceous hue or develop 
vesiculobullae and become erosive, often 
leave residual postinflammatory brown 
pigmentation; lesions recur in exactly the 
same sites upon readministration of the 
causative drug
-Distribution: anywhere 
-Mucosal involvement: usually affected
In acute lesions: 
Marked basal hydropic degeneration 
with lymphocyte tagging along the 
dermoepidermal junction and individual 
keratinocyte necrosis. Marked pigmentary 
incontinence is a typical feature. 
Subepidermal vesiculation in advanced cases. 
Lymphocytes, histiocytes, and neutrophils are 





-Timing: minutes to hours
-Type of skin lesions: transient, often pruritic, 
erythematous and edematous
papules and plaques 
angioedema is acute, asymmetric, pale or 
pink, subcutaneous swelling involving the 
face
-Distribution: anywhere on the body, 
including the palms, soles, and scalp
-Systemic manifestations: stridor if severe, 
abdominal pain, nausea, vomiting, and 
diarrhea
-Mucosal involvement: in angioedema
Urticaria: Variable dermal edema and 
sparse perivascular and interstitial mixed 
inflammatory infiltrate composed of 
lymphocytes, neutrophils, and eosinophils.
Erythema 
multiforme
-Type of skin lesions: typical targets, papular 
atypical targets, occasionally bullous lesions
-Systemic manifestations: fever, arthralgias
-Mucosal involvement: present
Combination of basal cell hydropic 
degeneration and keratinocyte apoptosis. 
The dermis shows heavy superficial 
lymphohistiocytic infiltrate associated with 




-Type of skin lesions: from limited or 
generalized psoriatic plaques to erythroderma 
and pustulosis -Distribution: anywhere, the 
palms and soles, nail changes and scalp 
involvement may also be observed.
The histological features overlap lichen 
simplex chronicus and psoriasis or may just 
be indistinguishable from psoriasis vulgaris.
Lichenoid drug 
eruption
-Timing: latent period of several months 
-Type of skin lesions: lichen planus-like but 
more eczematous, or pityriasis
rosea-like
-Distribution: generalized  and symmetric; 
often spares the “classic” sites of lichen planus, 
frequent photodistribution
-Mucosal involvement: usually spared
Histological features are indistinguishable 
from typical lichen planus plus focal 
parakeratosis and spongiosis. The epidermis 
is often thinner and hypergranulosis is less 
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DISCUSSION
The primary incidence of CADRs calculated in this 
study was 0.28% (78 patients with CADRs) from a to-
tal number of 27,093 outpatients attending the Der-
matology clinic in Kasr El Aini, Cairo University, in a 
period of 6 months.
Similar studies performed among outpatient 
dermatology clinics were limited in number and re-
ported variable incidence rates with variable dura-
tion (13). Indian studies, such as those by Chatterjee 
et al. (14) and Saha et al. (2), reported an incidence of 
Vasculitic drug 
eruption
-Timing: 7 to 21 days
-Type of skin lesions: purpuric papules, 
urticaria-like lesions, hemorrhagic blisters, 
pustules, digital necrosis, and ulcers 
-Distribution: primarily on the lower 
extremities
-Systemic involvement: is very unusual but 
may be fever, myalgias, arthralgias, and/or 
headache, arthritis, nephritis, peripheral 
neuropathy, and gastrointestinal bleeding.
Histological features of leukocytoclastic 
vasculitis.
Acneiform  drug 
eruptions
-Type of skin lesions: papules and/or pustules
 -Distribution: primarily on the face and upper 
trunk, the same sites favored by acne
Histological features of acne vulgaris.
Hyperpigmentation 
and ochronosis
-Timing: over months or years
-Type of skin lesions: purple, yellow or blue-
gray cutaneous hyperpigmentation, blue-
black dermal discoloration 2ry to prolonged 




Histological features depend on detection of 
the incriminated pigment (according to its 
type) either within the epidermis (melanin 





-Timing: over a period of
months or even years
-Type of skin lesions: erythematous to violet 
papules, plaques, or nodules
-Distribution: localized or generalized
-Systemic involvement: often associated 
lymphadenopathy
Dense superficial perivascular or band-
like infiltrate composed of lymphocytes, 
histiocytes, eosinophils, and atypical 
lymphoid cells with irregular enlarged and 





-Type of skin lesions: erythema and peeling 
scaling
-Distribution: >80-90% of the skin surface
-Systemic involvement: peripheral 
lymphadenopathy hypoalbuminemia, facial 
edema, thermoregulatory disturbances, and 
hepatomegaly
Non-specific features. Parakeratosis, 
psoriasiform hyperplasia and variable mild 
spongiosis. Dermal chronic inflammatory  





Table 4. Number of patients and their percentages of different types of CADRs detected in our study:
CADRs Percentage Number of Patients
SJS/TEN‡ 15.39% 12
Lichenoid Drug Eruption 15.39% 12
Exanthematous Drug Eruption 14.10% 11
Vasculitic Drug Eruption 11.54% 9
Fixed Drug Eruption 8.97% 7
Psoriasiform Drug Eruption 8.97% 7
Urticarial Drug Eruption 7.69% 6
Uncommon Types 17.95% 14
‡TEN: toxic epidermal necrolysis
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2.6% (739 patients among a total number of 27,726 
patients) and 0.28% (72 patients among a total 
number of 25,773 patients) of CADRs, respectively, 
over one year. In 2015, Qayoom et al. (15) reported a 
low incidence of 0.16% (92 patients), also over year, 
among a total of 48,238 patients attending the der-
matology outpatient clinic in Kashmir Valley, India, 
whereas Talib et al. (16) reported an incidence of 0.2% 
(134 patients) in a retrospective one-year study in 
Malaysia among a total of 69,849 patients attending 
the dermatology outpatient clinic. The low incidence 
rate of CADRs in our study can be explained by the 
fact that Kasr El Aini is a tertiary care unit and receives 
the most complicated cases, while minor drug reac-
tions and self-limiting cases often go unreported as 
they can be easily managed in the primary care unit. 
Comparable or even higher incidence of CADRs was 
reported among inpatients. Charli-Joseph et al. (17) 
reported an incidence of 2%-3% among inpatients. 
These rates among inpatients could be explained by 
the multiple drugs used and the underlying illness 
and co-morbidities among hospitalized patients. 
The mean age of patients with CADRs in our 
study was 41.7±14.84 years, which is relatively high 
compared with other studies (2,6,14,16). Two similar 
Indian studies (15,18) reported similar results, with a 
mean age of 37±30.12 and 39.6±16.77, respectively. 
In our study, there was a female predominance with a 
male:female ratio of 1:1.69. In contrast, Chatterjee et 
al. (14) reported a male predominance with a male:
female ratio of 1:0.87. This difference in the demo-
graphic profile can be explained by the difference 
in the demography of the patients, as there was a 
female predominance among the total patients at-
tending the clinic. 
The most common drug reaction patterns re-
ported in our study were SJS/TEN (15%) and lichen-
oid drug eruptions (15%). Two studies conducted in 
Malaysia (6,16) reported that SJS/TEN was the sec-
ond most common type of drug reaction (9.7%). In 
contrast, most studies reported that exanthematous 
drug eruption was the most common drug reaction 
(2,16,19).
A high incidence of SJS/TEN has been reported in 
Indian studies (18,20,21), while Western studies (22) 
reported the occurrence of SJS/TEN as a rarity. This 
might reflect the close surveillance, monitoring, and 
reporting of any drug reaction in the Western health 
systems, with the tendency to withdraw any suspect-
ed drugs even in cases of minor skin reactions. 
Very few studies highlighted the time lag be-
tween the initiation of the drug intake and the onset 
of the reaction as in our study. In our study, the mean 
time of onset was 10 days, with a minimum duration 
of one day and maximum duration of 365 days. In 
2015, Talib et al. (16) reported a mean of duration of 
2 weeks, with a minimum duration of 5 minutes and 
a maximum duration of 120 days. This wide range of 
variation may be due to total dependence patient 
self-reports (which may lack accuracy depending on 
the educational level of the patient), as the patient 
history was our main reference in the outpatient der-
matology clinic, unlike hospitalized patients where 
a medical record is available, which includes the ex-
act time of administered drugs, dosages, and drug 
forms. 
In our study, we compared the duration of drug 
intake, the duration between initiation of drug and 
onset of the reaction, and the duration of the erup-
tion in severe CADRs versus other non-severe types 
of CADRs, all of which had a statistically significantly 
longer duration in other non-severe types of CADRs. 
On reviewing the literature, no similar studies com-
paring these data in severe CADRs versus other non-
severe types were found; this may be due to the natu-
ral course of the severe CADRs which require prompt 
intervention to lower mortality in addition to causing 
severe morbidity. 
Severe CADRs comprised 19.2% of total CADRs 
in our study, which was similar to other studies per-
formed in Malaysia that showed a slightly higher rate 
Table 5. The most common drug category in each type of cutaneous adverse drug reaction (CADR)
CADRs Category Number of patients Percentage
Exanthematous drug eruption Antibiotics 6 54.50%
Fixed drug eruption Analgesics 6 85.70%
Lichenoid drug eruption Analgesics 11 91.70%
Psoriasiform drug eruption Anticonvulsants 3 42.90%
TEN‡ Antibiotics 6 50.00%
Urticarial drug eruption Antibiotics 4 66.70%
Vasculitic drug eruption Analgesics 4 44.40%
Uncommon Antibiotics 5 35.70%
‡TEN: toxic epidermal necrolysis
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Table 6. Comparison between severe cutaneous adverse drug reactions (CADRs) and other non-severe 
types of drug eruptions regarding the interval (duration) of drug intake, duration between initiation of 
drug, and onset of the reaction and duration of the eruption
Duration 
Parameters   P-value*
Severe CADRs   Other non-severe types of  CADRs
Mean SD Median Minimum Maximum Mean SD Median Minimum Maximum
Duration of drug 
intake (days)
7.20 6.39 5.00 1.00 20.00 8.76 9.79 7.00 1.00 545.00 0.008
Duration between 
initiation of drug and 
onset of eruptions 
(days)
9.07 6.11 7.00 2.00 21.00 3.95 3.46 10.00 1.00 365.00 0.040
Duration of the 
eruption (days)
8.60 5.04 7.00 3.00 21.00 3.62 7.63 10.00 1.00 365.00 0.010
*P-value (significant if <0.05); SD: standard deviation
of 24.5% (16). This high percentage may be attributed 
to referral of most of the severe CADRs to our derma-
tology clinic as they could not be managed in a pri-
mary care unit, while minor rashes could be treated 
by other health care facilities. 
The most common implicated groups of drugs 
causing CADRs in our study were NSAIDs (19.22%), 
antimicrobials (16.6%), and anticonvulsant drugs 
(6.4%). These percentages were lower than other 
studies, which reported that antimicrobials (57.33%), 
NSAIDs (21.3%), and anticonvulsant drugs (17.33%) 
represented the majority of the offending drugs (15). 
These low percentages in our study in comparison 
with other studies may be attributed to the high per-
centage of patients (51.28%) who could not recall the 
name of the incriminated drug. 
Among NSAIDs, ibuprofen was the most common 
implicated drug causing CADRs in our study, which 
was similar to the study by Chattopadhyay and Chakr-
bart (23) that reported ibuprofen as the second most 
common implicated NSAID causing CADRs, following 
diclofenac. However, this is in contrast to Qayoom et 
al. (15), who reported piroxicam followed by diclof-
enac as the most common NSAIDs causing CADRs. 
Among antimicrobials in our study, beta-lactam 
antibiotics were the most common category of drugs 
causing CADRs (10.26%), followed by sulfonamides 
(2.56%) and quinolones (2.56%). This is in contrast to 
Qayoom et al. (15), who reported quinolones as the 
most common antimicrobial causing CADRs. In ad-
dition, a 6-year study from Chandigraph, India and a 
multicenter analysis from Italy reported sulfonamides 
as the most common implicated drugs causing CADRs 
(24,25).
Phenytoin (2.56%) and carbamazepine (1.28%) 
were the most common drugs among the anticon-
vulsant group of drugs causing CADRs in our study. 
This was found to be similar to several previous stud-
ies (14,15,18,25). Other implicated anticonvulsants in 
our study were lamotrigine (1.28%) and carbamaze-
pine (1.28%). 
CONCLUSION
It is notable that the incidence of CADRs in our 
study was similar to incidences reported in different 
countries but the incidence of life-threatening reac-
tions like SJS/TEN was higher compared with studies 
conducted abroad.
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